Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 17;9(9):1247.
doi: 10.3390/biomedicines9091247.

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Iván Henríquez  1 , Mack Roach 3rd  2 , Todd M Morgan  3 , Alberto Bossi  4 , Junior A Gómez  1 , Oscar Abuchaibe  5 , Felipe Couñago  6
Affiliations
Review

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Iván Henríquez et al. Biomedicines. .

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.

Keywords: androgen deprivation therapy; mCRPC; novel therapies; prostate cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Siegel R.L., Miller K.D., Goding Sauer A., Fedewa S.A., Butterly L.F., Anderson J.C., Cercek A., Smith R.A., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:145–164. doi: 10.3322/caac.21601. - DOI - PubMed
    1. El Cáncer en Cifras-SEOM: Sociedad Española de Oncología Médica © 2019 [Internet] [(accessed on 17 December 2020)]. [Citado 23 de Diciembre de 2020] Available online: https://seom.org/prensa/el-cancer-en-cifras.
    1. Valero J., Peleteiro P., Henriquez I., Conde A., Piquer T., Lozano A., Soler C.C., Muñoz J., Llescas A., Jove J., et al. Age, Gleason and PSA are important prognostic factors for survival in metastático castration-resistant prostate cancer. Results of the Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR) Clin. Transl. Oncol. 2020;22:1378–1389. doi: 10.1007/s12094-019-02274-w. - DOI - PubMed
    1. Scher H.I., Solo K., Valant J., Todd M.B., Mehra M. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS ONE. 2015;10:e0139440. doi: 10.1371/journal.pone.0139440. - DOI - PMC - PubMed
    1. Scher H.I., Morris M.J., Stadler W.M., Higano C., Basch E., Fizazi K., Antonarakis E.S., Beer T.M., Carducci M.A., Chi K.N., et al. Trial Design and Objectives for Castration-. Prostate Cancer: Updated Recommendations from the Prostate cancer Clinical Trials Working Group 3. J. Clin. Oncol. 2016;34:1402–1418. doi: 10.1200/JCO.2015.64.2702. - DOI - PMC - PubMed